Ernexa Therapeutics’ “Trojan Horse” stem cells can infiltrate ovarian tumors in mice, boosting T cell activity and leading to ...

An ovarian germ cell tumor is a growth in a woman's ovaries. Most of these tumors aren’t cancer. Instead, they are “benign” growths. Cancerous germ cell tumors are rare. They make up only 2% ...

Ovarian cancer cells use mechanical force to move through tissue and colonize additional organs. A new study contributes to a body of work that will inform future treatments. Eventually ...

How ovarian cancer disables immune cells Date: October 23, 2024 Source: Weill Cornell Medicine Summary: Researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and ...

called adaptive NK cells, to remember ovarian tumors and effectively attack them. The discovery, published in Cancer Immunology Research, could pave the way for new, more powerful immunotherapies for ...

called adaptive NK cells, to remember ovarian tumors and effectively attack them. The discovery, published in Cancer Immunology Research, could pave the way for new, more powerful immunotherapies ...

According to the American Cancer Society (ACS), germ cell ovarian cancer is rare, accounting for 3% of ovarian cancer cases. They are most common in adolescents and young females between 15–19 ...

In particular, natural killer cells, are emerging as an optimal cell target for immunotherapy in ovarian cancer. Natural killer cells are a type of white blood cell responsible for eliminating ...

Although tumor-infiltrating T cells have been documented in ovarian carcinoma, a clear association with clinical outcome has not been established. CD3+ tumor-infiltrating T cells were detected ...

"Discovering tumor-associated antigens that T cells recognize is crucial for the success of immunotherapeutic approaches in ovarian cancer, where the growth of cells that form in the ovaries ...

called adaptive NK cells, to remember ovarian tumors and effectively attack them. The discovery, published in Cancer Immunology Research, could pave the way for new, more powerful immunotherapies ...